Clostridioides difficile: innovations in target discovery and potential for therapeutic success

Tanya M Monaghan, Anna M Seekatz, Benjamin H Mullish, Claudia C. E. R Moore-Gillon, Lisa F. Dawson, Ammar Ahmed, Dina Kao and Weng C Chan

ABSTRACT

Introduction: Clostridioides difficile infection (CDI) remains a worldwide clinical problem. Increased incidence of primary infection, occurrence of hypertoxigenic ribotypes, and more frequent occurrence of drug resistant, recurrent, and non-hospital CDI, emphasizes the urgent unmet need of discovering new therapeutic targets.

Areas covered: We searched PubMed and Web of Science databases for articles identifying novel therapeutic targets or treatments for C. difficile from 2001 to 2021. We present an updated review on current preclinical efforts on designing inhibitory compounds against these drug targets and indicate how these could become the focus of future therapeutic approaches. We also evaluate the increasing exploitability of gut microbial-derived metabolites and host-derived therapeutics targeting VEGF-A, immune targets and pathways, ion transporters, and microRNAs as anti-C. difficile therapeutics, which have yet to reach clinical trials. Our review also highlights the therapeutic potential of re-purposing currently available agents. We conclude by considering translational hurdles and possible strategies to mitigate these problems.

Expert opinion: Considerable progress has been made in the development of new anti-CID drug candidates. Nevertheless, a greater comprehension of CDI pathogenesis and host-microbe interactions is beginning to uncover potential novel therapeutic targets, which can be exploited to plug gaps in the CDI drug discovery pipeline.

1. Introduction

Clostridioides difficile is a gram positive, strictly anaerobic, spore-forming bacterium capable of colonizing the gastrointestinal tract, and a leading worldwide cause of antibiotic-associated and healthcare-acquired infectious diarrhea [1]. Although the majority of Clostridioides difficile infection (CDI) cases are triggered by antibiotic exposure, other risk factors include older age, immunosuppression, inflammatory bowel disease, and chronic kidney disease [2–4]. The epidemiology of C. difficile is evolving, with increasing reports of community-acquired C. difficile infection (CDI) in persons who are young and otherwise healthy [5]. The clinical spectrum ranges from asymptomatic carriage, mild infection with diarrhea to toxic megacolon and multiorgan failure in fulminant cases [2], where attributable mortality rates range between 30% and 60% [6].

Interruption of the gut the intestinal microbial composition, commonly referred to as microbial dysbiosis, to predominance by Proteobacteria rather than Firmicutes and Bacteroidetes is integral to CDI pathogenesis [7]. Once established in the gut, C. difficile produces the virulence factors TcdA and TcdB, toxins belonging to the larger clostralid glycosylating toxin family, with TcdB being more virulent [8]. Furthermore, adhesion and motility-associated factors, such as surface layer protein (SlpA), cell wall protein 84 (Cwp84), flagellar components, and the presence of C. difficile binary toxin CDT, all play roles in CDI pathogenesis [9,10]. Although certain ribotypes, such as 027 and 078, are associated with severe infection [11–13], determinants of disease severity and recurrence risk are largely shaped by the complex host immune response to CDI, much of which remains poorly understood. For example, anti-toxin antibodies play a protective role and prior studies have shown that low serum anti-toxin A and B antibody levels are associated with an increased risk of recurrent CDI [14,15]. However, when used in combination with standard-of-care antibiotics, only Bezlotoxumab, a fully human anti-toxin B monoclonal antibody, not Actotoxumab, a monoclonal anti-toxin A antibody, is effective in preventing CDI recurrence in clinical trials [16].

The mainstay of treatment for CDI is antibiotics, which may worsen dysbiosis, contributing to CDI recurrence. The
conventional first-line therapy for CDI is vancomycin, a glycopeptide antibiotic targeting mainly Gram-positive bacteria. An alternative is fidaxomicin, a narrow spectrum macrolide antibiotic, which is superior to vancomycin in preventing CDI recurrence, although it is not currently commonly used as first-line therapy due to its high cost. Although the Infectious Diseases of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA) recently recommended the use of fidaxomicin rather than standard course of vancomycin as the preferred therapy for an initial episode of CDI, its implementation will clearly depend upon available resources [17]. Metronidazole may still be used in a primary episode in younger patients with mild to moderate infection, although resistance is increasing [18].

Following treatment for the initial episode of CDI, approximately 15% to 30% of patients may experience CDI recurrence, and the risk continues to rise with each subsequent episode, reaching approximately 45% to 65% after the third episode [19]. Since conventional therapeutic options are limited, managing patients with recurrent CDI (rCDI) is a major clinical challenge. Thus, better and more targeted treatments for the initial episode of CDI is key to preventing rCDI. Pulsed tapered vancomycin is the usual treatment for rCDI. Bezlotoxumab has demonstrated modest efficacy in preventing CDI recurrence when used as an adjunct to CDI directed antibiotics, but due to high cost, its role in the rCDI treatment algorithm remains unclear. On the other hand, fecal microbiota transplantation (FMT) has shown very high efficacy in this patient population [20]. However, FMT is an untargeted therapy, and the risks of potential infectious transmission cannot be overlooked [21,22]. Defined microbial consortium would negate such risks. Recently, Microbial Ecosystem Therapeutics (MET-2) was shown in a small open-label trial of 19 patients to have similar efficacy to FMT [23]. Although the precise mechanisms of FMT or live microbial therapeutics are not well understood, several mechanisms have been shown to mediate the resolution of recurrent CDI [24,25].

In this review, we highlight new potential therapeutic targets for CDI treatment, examining different strategies. These range from repurposed drugs aimed at *C. difficile* to new precision therapeutics that target *C. difficile* virulence factors, as well as and precision immune- and epigenetic therapeutic approaches that modulate the host immune and inflammatory response (Figure 1). We also describe the perceived challenges in bringing these new approaches to the clinic.

2. Novel therapeutic strategies

2.1. *C. difficile* adhesins

Several adhesins on both the spore and vegetative cell types of *C. difficile* represent potential pathogenic targets to attenuate colonization, virulence, and recurrence. This section will review some of the recent advances made in targeting inhibition of *C. difficile* adhesion to host cells.

Recent evidence suggests that binding by exosporium proteins to mucin glycoproteins is key to initial colonization, involving both binding and internalization of the spore to the intestinal epithelium. In *vitro* binding studies demonstrated that CotE, a peroxiredoxin-chitinase protein, mediated binding to the mucin glycoproteins, as well as the monomers GlcNAC and GalNAC [26]. Infection with strains lacking CotE also resulted in increased survival in a hamster model of disease. The collagen-like protein BclA1 have previously been demonstrated to aid binding to the epithelial layer [27]. A recent study extended this observation, demonstrating in *vitro* that BclA3 mediates binding and internalization of the spore via the host proteins fibronectin and vitronectin [28]. Mice infected with a BclA3 mutant strain demonstrated reduced recurrence rates, suggesting that spore adhesion could contribute to the persistence of spores in the gut during antibiotic treatment. Blocking exosporium protein binding may thus represent a therapeutic target to not only decrease initial colonization of *C. difficile* but also prevent recurrence. Indeed, preliminary studies suggest that BclA3 epitopes can induce anti-spore IgG antibodies in a mouse model of infection, highlighting new vaccine targets to inhibit *C. difficile* entry and persistence [29].

The cell wall of *C. difficile* incorporates several surface layer (S-layer) proteins (SLPs) that promote adhesion and growth of vegetative cells. The *C. difficile* conserved gene *slpA* encodes for two SLPs, a high molecular weight (HMW-SLP) and low-molecular weight (LMW-SLP), that are major mediators of binding to the epithelium [30]. Pre-treatment of cells with purified SlpA or anti-slpA sera has been demonstrated to reduce *C. difficile* attachment to host cells in *vitro* [31]. Partial protection has been observed previously in mice vaccinated with SlpA [32]. More recently, administration of lactic acid bacteria that also express SLP orthologs engineered to express *C. difficile* SLPs could prevent CDI-induced death in a hamster model of infection [33].

The flagellar proteins fliC and fliD are involved in attachment to the epithelial layer, thus representing another target...
2.2. Biofilms

Like many pathogens, *C. difficile* has been shown to form biofilms in the gastrointestinal tract of mice [38] and hamsters [39], as well as in multispecies biofilms with representatives of the human gut microbiome [40]. The formation of biofilms has the potential to promote persistence and resistance to antibiotics [41,42]. *C. difficile* genomes contain a luxS gene homolog, which encodes for a common signaling molecule, autoinducer-2, involved in quorum sensing to initiate biofilm formation and transcription of virulence factors [43]. In addition to LuxS, flagella, the cell wall protein Cwp84, and the master regulator of sporulation SpoA have been involved in biofilm formation in vitro [41,44,45]. Biofilms form a protective shield around vegetative cells and spores which confers resistance to vancomycin [41,42] and oxygen [46]. Extracellular DNA and spore frequency has also been associated with biofilm formation, further demonstrating the importance of adhesion and sporulation proteins in biofilms [42]. Although the role of biofilm formation remains unclear during *in vivo* infection, a recent study demonstrated increased growth and germination when *C. difficile* was encased in a biofilm compared to *C. difficile* spores in a chemostat model consisting of pooled human feces [40]. Interference with biofilm formation, or disassembling established biofilms with DNase treatment [42], as well as related mechanisms like sporulation, could thus render *C. difficile* more susceptible to antibiotic therapies and/or prevent persistence of spores to reduce recurrence.

More recently, there is interest in targeting mixed bacterial populations to prevent *C. difficile* biofilm formation and thus persistence in the gut. *Bacteroides fragilis*, a gut commensal microbe that has been negatively associated with *C. difficile* during infection, was demonstrated to inhibit *C. difficile* biofilm formation *in vitro* in co-culture [44]. The presence of LuxS was observed to contribute to *C. difficile* growth inhibition in this co-culture [44], suggesting different metabolic and signaling pathways for mono- vs mixed-populations. In a bioreactor model consisting of human feces, *C. difficile* has been observed to co-colonize with *Fusobacterium nucleatum*, another prevalent human gut commensal bacterium [47]. Aggregation between the two was diminished when *C. difficile* flagella or the RadD protein of *F. nucleatum* was removed. Targeting of non-*C. difficile* factors, such as proteins of other bacteria that interact with *C. difficile* directly, could be a unique therapeutic landscape.
2.3. P-Cresol production

An unusual feature of *C. difficile* among the gut microbiome is its ability to produce high concentrations of the antibacterial compound para-cresol. In *C. difficile*, p-cresol production occurs either through the fermentation of tyrosine via the intermediate para-hydroxyphenylacetate (p-HPA) [48], or via turnover of exogenous p-HPA [49] present in the human gut. This decarboxylation of p-HPA to p-cresol is performed by the HpdBCA decarboxylase encoded by the hpdBCA operon [48]. Dawson et al have shown that each subunit (hpdB, hpdC and hpdA) is essential for p-cresol production [50]. The production of p-cresol by *C. difficile* has a deleterious effect on the gut microbiome, promoting dysbiosis, by targeting the Gram-negative cell envelope, which confers a fitness advantage over other intestinal bacteria and enhances relapse of CDI [51]. *C. difficile* is only one of four gut bacteria (*Blaurococcus alcaligenes*, *Romboutsia lituseburensis* and *Olenella ulii*) capable of high-level p-cresol production (>100 µM), with an additional 55 gut bacteria capable of producing <10 µM [52]. However, the HpdBCA operon is highly conserved in all the sequenced *C. difficile* isolates [51], and interestingly only the three other high p-cresol producing gut bacteria had orthologues to the hpdBCA operon (>30% amino acid sequence identity). Interestingly, the hypervirulent strain R20291 produced significantly more p-cresol than the 630 strain and is more tolerant to p-cresol [53]. Regulation of p-cresol production involves induction of the HpdBCA decarboxylase via the presence of p-HPA, in a concentration dependant manner [49], indicating that sensing and responding to p-HPA is key to p-cresol production. The p-cresol biosynthesis pathway, and more specifically the HpdBCA decarboxylase, is an alternative druggable target, which would have minimal perturbations on the healthy gut microbiome and thereby reduce the potential off target effects of broad-spectrum antibiotics that promote dysbiosis.

Detection of p-cresol could also enhance diagnosis of CDI. The presence of p-cresol can be detected by gas liquid chromatography using a portable Z-Nose [53] and has been shown to be present in stool samples of mice infected with *C. difficile* [51]. The Z-Nose is an ultra-rapid analytical device which allows the real-time monitoring of volatile compounds [54], such as p-cresol [53]. The detection of p-cresol in stool samples at point-of-care would potentially speed up diagnosis and treatment of CDI.

2.4. Phage-based therapeutics

Bacteriophage are bacterial viruses, which can infect and kill certain bacteria. Phage have a narrow host range, which makes them a potentially useful therapeutic to target specific pathogenic bacteria [55]. There are main two types of phage, lytic and temperate. Temperate phage have the capacity to be either lytic or lysogenic depending on the host and environmental conditions, however only lytic phage show therapeutic potential. To date, a limited number of *C. difficile* specific lytic phage have been identified. Phage produced endolysins/lysin rapidly degrade cell wall peptidoglycan to facilitate release of bacteriophage progeny following replication [56]. Bacteriophage-derived endolysins and their derivatives have shown efficacy as a novel class of antibacterial agents. *C. difficile* bacteriophages produce amidase and endolysin. Mondal et al. [57] identified that recombantly expressed cell wall hydrolase (CWH) lysin from *C. difficile* phage, phiMMP01, was active against *C. difficile* and this activity could be enhanced by removing the N-terminal cell wall binding domain, creating CWH351 – 656 [58]. Interestingly, Mayer et al. [58], identified that truncation of the endolysin CD27L from phage ΦC27L, retaining just the N-terminal domain, CD27L1–179 increased lytic activity against *C. difficile* [58]. This recombinant CWH (CWH351 – 656) inhibits spore outgrowth in vitro, which the authors suggest is critical in preventing the spread and recurrence of *C. difficile* infection [57]. Phage lytic enzymes have been shown to achieve a 4-log reduction in *C. difficile* vegetative cell viability in 5 hours after external application [59], potentially making them a narrow spectrum target for CDI. However, the lack of naturally occurring strictly lytic phages in *C. difficile* has significantly impacted phage therapy [60], but the use of recombinant lytic phage protein has opened a door for targeted phage therapy.

2.5. FabK inhibitors

Fatty acids play a crucial role in the maintenance of the integrity of bacterial cell membranes, and their biosynthesis, as part of the non-mammalian type II fatty acid synthase (FASII) pathway, is mediated by a multitude of interlinked acyl carrier proteins (ACPs) in the cytoplasm [61,62]. Substrates of this pathway are bound to ACPs such as FabD, FabF and FabG, and undergo a series of reactions to extend their acyl chains; each elongation cycle is culminated by reduction, which is catalyzed by an enoyl-acyl carrier protein reductase. These enzymes thus serve as suitable antimicrobial targets, an example of which is isoniazid, an antibiotic used in treating *Mycobacterium tuberculosis*, and one which functions by inhibiting the reductase FabI [63]. Since bacterial species utilize specifically distinct enoyl-ACP reductases, its inhibition additionally provides a selective antimicrobial target. For instance, triclosan, another known FabI inhibitor, does not inhibit reductases such as FabK and FabV [64,65]. Although not as extensively studied as FabI, FabK has previously been reported as the sole reductase present in *Streptococcus pneumoniae* [66], and this has led to the identification of FabK inhibitors [67], including compounds derived from phenylimidazole [68].

Over the last few years, FabK has been found to be particularly noteworthy in the context of CDI. Unlike almost all other gut bacteria, which utilize only FabI or both FabI and FabK, *C. difficile* has been shown to exclusively make use of FabK [69], thereby making it an ideal candidate for selective inhibition by FabK inhibitors, and concurrently limiting the wider damage to the gut. Indeed, a follow-up study has demonstrated considerable efficacy of a range of phenylimidazole-derived compounds in inhibiting proliferation of *C. difficile*, whilst having a minimal impact on other gut bacterial species [70]. The significance of targeting FabK in *C. difficile* is
further highlighted by the fact that unlike current anti-CDI therapies, it not only limits sporulation (a key factor in disease recurrence), but given that the expression of FabK is itself controlled by the transcription factor FapR, its FASII system has been shown to resist being bypassed in the presence of exogenous lipids; the latter is in contrast to the interaction seen with most other gut bacterial species, where extracellular lipids in the gut are known to circumvent FASII, thus reducing the efficacy of any therapies that target this system [69]. Overall, FabK has demonstrated significant in vitro potential as a selective C. difficile target, and further scientific enquiry may allow FabK inhibitors to become a targeted treatment of CDI.

### 2.6. Toxin-targeted therapies

Targeting the highly pathogenic toxins of C. difficile represents a promising therapeutic approach to treat the symptoms associated with infections. Tam et al. [71] used chemical libraries composed of diverse small molecules consisting of natural products, drugs approved for human use, and molecules with known biological activity to identify 66 compounds capable of protecting cells from TcdB-induced rounding. These include toxin-modifying compounds, a toxin-stabilizing molecule (methyl cholate), inhibitors of endosomal acidification (bafilomycin A1, ammonium chloride, carboxylic ionophore monensin, aminacrine, amodiaquine, quinacrine, prazosin), and noncompetitive inhibitors of glucosyltransferase (GTD) activity (phloretin and its derivatives). In more recent work by the same authors [72], primary and secondary bile acids, which are known to play a role in C. difficile germination and outgrowth, were shown to directly modulate the structure and function of TcdB. Bile acid binding through the C-terminal combined repetitive oligopeptide repeats (CROP) domains, induces a major conformational change in TcdB structure that prevents receptor binding and uptake into cells. In follow on work, the team screened 2401 small molecules and identified 15 with a bile-acid-like mechanism of action. Alongside methyl cholate, they identified other hits including chenodeoxycholic acid, cholic acid, and lithocholic acid, betulinic acid, oleic acid, asiatic acid as well as ethavereine [72]. Nonetheless, the therapeutic use of bile acids may be problematic due to the potential for overloading physiological functions of bile acids, particularly, signal transduction pathways and bile acid recycling processes. Of note, the microbiota is also altered after bile acid treatment [73].

Other small-molecule inhibitors of C. difficile toxins include ebselen (1; Figure 2), a synthetic organoselenium compound, work mechanistically through inactivation of TcdA [74] and TcdB via inhibiting the function of the auto-processing domain or the glucosyltransferase domain (GTD) [75].

Simeon et al. [76] report the TcdB-neutralizing capabilities of a series of monomeric and dimeric designed ankyrin repeat proteins (DARPins). Their findings show that DLD-4 displayed an approximately 330-fold higher potency than the commercially available anti-TcdB monoclonal antibody Bezlotoxumab in the same assay, and also protected mice from a toxin challenge in vivo. Competitive ELISA studies showed that the DARPins of DLD-4-1.4E and U3 interfere with the interaction between TcdB and its receptors chondroitin sulfate 4 (CSPG4) and frizzled class receptor 2 (FZD2), respectively. These highly

---

**Figure 2.** Examples of reported anti-C. difficile compounds.
potent DARPin-based antitoxins possess the potential to be
developed into therapeutics to treat CDI and/or prevent its recurrence.

In addition to the large clostridial toxins TcdA and TcdB, a
third *C. difficile* binary toxin (CDT) is associated with the most
serious outbreaks of drug-resistance CDI. However, no therapeu-
tic targeting strategies for CDT have been FDA-approved.
New research has begun to elucidate the structure of the cell-
binding component of CDT (CDTb), revealing a di-heptamer
macromolecular assembly, and represents a starting point for
developing structure-based drug-design strategies to target *C.
difficile* [77].

Furthermore, new research has shown that defensins repre-
sent interesting therapeutic candidates to treat CDI. Defensins,
as a prominent family of antimicrobial peptides (AMP), are
major effectors of the innate immunity with a broad range of
immune modulatory and antimicrobial activities. Typically,
defensins promote local unfolding of the affected toxins upon
binding, destabilize their secondary and tertiary structures,
increase susceptibility to proteolysis, and leads to their pre-
cipitation [78]. Giesemann et al. [79] were the first to reveal
that human alpha defensins human neutrophil protein (HNP)-
1, HNP-3, and enteric HD-5 inhibited TcdB-induced cytotoxicity
in multiple cell lines. These α-defensins inhibited the glucosy-
lation of Rhp proteins by toxin B. More recently, Korbmacher
et al. [80] have shown that human antimicrobial peptide α-
defensin-5 can efficiently neutralize CDT as well as TcdA and
TcdB in cultured human intestinal epithelial cells. The same
group of researchers has also reported that human α-defensin-
1 protects cells and human intestinal organoids from the
cytotoxic effects of TcdA, TcdB, CDT and their combination,
and in mice, was also able to reduce TcdA-induced damage of
intestinal loops in vivo [81].

### 2.7. Gut microbial metabolites: inhibitory role in
sporulation and germination

Gut microbiota-derived metabolites impact upon numerous
different aspects of metabolic and immune function within
mammalian hosts [82]. Recognition that gut microbiota per-
turbation is a key contributor to CDI pathogenesis and that its
restoration (i.e. via fecal microbiota transplant or FMT) is an
efficacious treatment strategy, has fueled interest in the
exploitation of gut microbial-derived metabolites as anti-*C.
difficile* therapeutic agents [83].

Bile acids have been one particular focus, with interest
deriving from the observation that different bile acids variably
affect the ability of *C. difficile* to undergo vegetative growth or
germination. Specifically, the primary conjugated bile acid,
taurocholic acid (TCA), facilitates *C. difficile* spore germination
[84], while secondary bile acids (including deoxycholic acid
(DCA) limit the growth and toxin activity of *C. difficile*
vegetative cells [85]. The biotransformation of primary to secondary
bile acids *in vivo* is undertaken by enzyme systems produced
by the gut microbiota but not mammals, and principally by
two enzymes called bile salt hydrolase (BSH; which hydrolyses
a glycine or taurine group from conjugated primary bile acids)
and 7a-dehydroxylase (which converts unconjugated primary
bile acids into secondary bile acids) [86]. Recurrent CDI
patients develop gut enrichment of TCA but deficiency of
secondary bile acids, which appears principally attributable
to gut microbial BSH or 7α-dehydroxylase loss following
prior antibiotic exposure [87–91]. Restoration of gut BSH func-
tionality occurs after FMT for rCDI in humans [90], and delivery
of 7α-dehydroxylase into rodent models is at least partially
protective against CDI [92,93]. As such, the targeted adminis-
tration of gut microbiota members with high bile-metaboliz-
ing functionality, or the administration of purified BSH and/or
7α-dehydroxylase, merits further consideration as an anti-CDI
treatment strategy. There are several intuitive reasons that
favor restoration of BSH-producing organisms as such a treat-
ment approach compared to 7α-dehydroxylase-producers; for
instance, BSH has relative insensitivity to oxygen and robust
activity over a wide pH range, while 7α-dehydroxylase is a
highly oxygen-sensitive enzyme [94]. An alternative possible
strategy suggested by these data may be administration of
exogenous secondary bile acids. However, such an approach
would not remove pro-germinant bile acids (such as TCA) as
an enzyme-based strategy would. Furthermore, excess intesti-
nal secondary bile acids (including DCA) are recognized as a
direct cause of colorectal tumorigenesis [95], and considerable
care in dose titration would be required. An alternative pro-
posed strategy may involve disruption of the interaction with
TCA with the *C. difficile* bile acid germination receptor; bile
acid analogues, such as CamSA (2; *Figure 2*) that act in this
way have shown promise in pre-clinical models [73,96].
Although CamSA showed potent activity against both *C.
difficile* strains 630 and VPI 10463 [73,96], it is ineffective toward
the hypervirulent *C. difficile* strain R20291. In a follow-up study,
Sharma et al. discovered that compound (3; *Figure 2*) is a
potent inhibitor of *C. difficile* R20291 spore germination [97].

A further route through which bile acids interact with their
host is as endogenous ligands for host cell receptor systems,
including the nuclear receptor farnesoid X receptor (FXR).
Recurrent CDI patients have low levels of FXR signaling, with
FMT restoring this [98]. Administration of a potent FXR ago-
nist, obeticholic acid (4; *Figure 2*), to a high-fat diet CDI mouse
model resulted in a reduced *C. difficile* burden, as well as
reduced diarrhea and improved intestinal inflammation [99];
similarly, treatment of a mouse CDI model with the tertiary
bile acid, ursodeoxycholic acid (UDCA), resulted in increased
FXR-related transcripts and associated reduced intestinal
inflammation [100].

A further class of microbial metabolites of interest are short
chain fatty acids (SCFAs), which are derived primarily from
bacterial fermentation of partially and non-digestive carbohy-
drates within the colon. Recent studies demonstrated a defici-
cy in SCFAs in the GI tract in CDI, and their restoration to
pre-morbid levels via FMT [89,91,101]; *in vitro* experiments
highlighted close negative correlations between levels of the
five carbon SCFA valerate and growth of a range of *C. difficile*
ribotypes [101]. While the volatile nature of SCFAs and their
potent odor presents challenges to their direct oral delivery,
the administration of glycerol trivalerate (with valerate liber-
atated in the small intestine through pancreatic lipases) was
associated with reduced *C. difficile* burden in a mouse model.
Medium- and longer-chain fatty acids may have even more potent inhibitory effects against C. difficile [102,103] and these also hold promise (either via dietary manipulation, or exogenous administration) as anti-CDI agents.

Successful FMT for recurrent CDI has also been associated with changes in a number of other gut microbial metabolites [83], although whether these are purely incidental changes or hold scope for exploitation as novel targeted treatment approaches is currently undefined. Conversely, a range of other gut microbial metabolites have been recently associated with maintenance of gut epithelial integrity (e.g. tryptophan metabolites) [104], but it is currently poorly explored as to whether these metabolite systems hold relevance to CDI.

3. Host-directed therapeutics

Recent insights into host–pathogen interactions, pathogenesis, inflammatory pathways, and the host’s innate and adaptive immune responses are leading to identification and development of host-directed therapeutics with different mechanisms of action [105]. Emerging evidence suggests that host-directed therapeutic approaches may find utility in treating severe and refractory CDI.

3.1. VEGF-A

Once such potential host target is vascular endothelial growth factor A (VEGF-A), which seems to be important in promoting C. difficile pathogenesis. Toxigenic C. difficile is associated with increased colonic vascular permeability in CDI mice and elevated levels of VEGF-A in vivo and in human colonic mucosa exposed to toxins ex vivo. Both toxins A and B induced VEGF-A production in human colonocytes through HIF-alpha, p38-MAPK and MEK1/2 signaling pathways. By blocking the main receptor of VEGF-A (VEGFR-2) with a kinase inhibitor SU1498 (5; Figure 2), there was a significant reduction of vascular permeability in CDI mice, and significantly attenuated weight loss. Similarly, treatment of CDI mice with anti-VEGF-A antibody attenuated vascular permeability and protected mice from infection and improving overall survival. It is thus surmised that humanized anti-VEGF-A monoclonal antibodies such as Avastin (Bevacizumab) and its biosimilar Mvasi, which have been approved to treat various cancers and eye diseases, could prove useful drugs in managing CDI [106].

3.2. Intestinal ion transporters

Several intestinal ion transporters, which ensure fluid and electrolyte homeostasis, are implicated in infectious and inflammatory diarrhea [107] and may represent promising host-directed therapeutic targets against C. difficile.

In C. difficile, toxin B (TcdB) causes a pronounced inhibition of Na+/H+ exchanger 3 (NHE3) activity in placental and renal cell lines. Here, TcdB exposure inhibits NHE3 by dephosphorylation and redistribution of ezrin, which normally anchors NHE3 to the cytoskeleton [108]. Furthermore, patients with rCDI have decreased NHE3 in the apical membranes of their enterocytes [109], which contribute to the diarrheal phenotype of CDI. Injection of C. difficile and CDI patient stool supernatant resulted in a substantial decrease in NHE3 mRNA and protein levels compared with broth-injected (control) human intestinal organoids. C. difficile toxin inhibition of NHE3 alters the intestinal environment producing a high [Na+]i, and a more alkaline fluid, which enhances C. difficile proliferation and inhibits competitive Clostridial groups proliferation. It follows that upregulation of NHE3 may provide a means to reestablish intestinal homeostasis and thus shift the microbiota toward a pre-morbid or pre-CDI composition [109].

The down-regulated in adenoma (DRA) protein, encoded by SLC26A3, a key Cl−/HCO3− exchanger protein in the intestinal epithelial luminal membrane, participates in electroneutral NaCl absorption, together with Na+/H+ exchangers such as NHE3 [110]. Coffeng et al. demonstrated that the expression of Slc26a3 protein was significantly reduced in response to C. difficile toxins TcdA and TcdB in Caco 2 intestinal epithelial cells. However, these toxin-mediated effects were specific to DRA, as NHE3 and Slc26a6 protein and mRNA levels were unaffected. This discrepancy with what has been reported by Engevik et al. may be due to variations in the model system and/or cell type used in addition to the different effects of C. difficile strains and varying concentrations of toxins [111]. Additionally, purified TcdA and TcdA and TcdB, but not TcdB alone, resulted in a decrease in colonic DRA protein levels in a toxigenic mouse model of CDI. Moreover, patients with rCDI exhibited a significant loss in colonic Slc26a3 protein, indicating that the downregulation of DRA by C. difficile toxins is likely occurring at the post-transcriptional level.

These results suggest that DRA and NHE3 may be potent novel targets for therapeutic management of CDI-associated diarrhea [110]. In this regard, the probiotic L acidophilus has been shown to increase mRNA for DRA in colonic epithelial cells by transcriptional activation of its promoter [112]. Similarly, lysophosphatidic acid (LPA) stimulates NHE3 trafficking to the apical membrane and its activity, inhibits Cl−/OH− exchange, and both expression of and apical abundance of DRA in Caco-2 cells [113,114]. NHE3 activation by LPA is attributable to the LPA5 receptor and was abolished in the absence of NHERF2 [115,116]. LPA also increases DRA promoter activity, which involves the LPA2 receptor and the phosphatidylinositol 3-kinase/AKT serine/threonine kinase 1 (PI3K/AKT) pathway [113]. Hence, these results suggest that LPA, or agents that target its receptor, may be efficacious as anti-diarrheal agents [107].

3.3. MicroRNAs

MicroRNAs (miRs) are small, non-coding RNAs consisting of 16 to 22 nucleotide sequences that are implicated in the regulation of gene expression by repressing the expression of target genes by degrading or inhibiting translation of the targeted mRNA [117]. These non-coding regulators of gene expression at the post-transcriptional level have an essential role in targeting transcripts encoding proteins of intestinal tight junction (TJ) and their regulators [117]. Since a defective tight-junction barrier has been implicated in inflammatory and infectious diarrhea, including C. difficile, the therapeutic potential of using specific
microRNAs to target the intestinal TJ barrier might be of benefit. Recent work from our own group has identified the upregulation of 64 miRNAs in the circulation of patients undergoing successful FMT for rCDI [118]. In a murine model of relapsing CDI, RT-qPCR analyses of sera and cecal RNA extracts demonstrated suppression of these microRNAs, an effect that was reversed by successful FMT. In mouse colon and human colonoids, TcdB mediated the suppressive effects of CDI on miRNAs. We confirmed that the downregulation of miRNAs is likely through the suppression of Drosha (an enzyme which plays a central role in microRNA biogenesis) by CDI/TcdB and is restored following FMT. We further demonstrated that FMT-regulated miRNAs including miR-23a, miR-150, miR-26b, and miR-28 target directly the 3’UTR of target IL-12B, IL-18, FGF21 and TNFRS9, respectively. Further, a combination of two specific miRNAs, miR-23A and miR-150 demonstrated cytoprotective effects against TcdB.

Altogether, restoring miRNA expression in intestinal epithelial cells should prove beneficial in improving the intestinal barrier function in CDI. Nonetheless, significant further studies are required to understand which constituents of the gut microbiota or microbiota-derived metabolites within FMT may modulate expression of miRNAs.

Moreover, despite the progress made in understanding the role of miRNAs in mediating clinical efficacy of FMT and in maintaining gut barrier function, the clinical translation of these molecules to therapy remains in its infancy. The paucity of vehicles available for safe delivery of miRNAs, and ongoing concerns for toxicity due to off-target effects, remain major obstacles to rapid clinical translation. Continued efforts to improve the challenges inherent in miRNA therapy and substantial market investment should soon see the development of patient-specific miRNA mimics or antimiRs with a goal of effective personalized therapy for multiple conditions, including infectious diseases.

3.4. Immunity-based targeting

Impaired innate and adaptive immune responses have been implicated in disease severity [119–123], and treatments focused on inducing immune responses relevant to *C. difficile* clearance and recovery from CDI represent novel treatment options. Three non-antibiotic FDA-approved drugs, amoxapine (an antidepressant), doxapram (a breathing stimulant), and trifluoperazine (an antipsychotic), were demonstrated to significantly protect against experimental CDI in a mouse model by reducing bacterial burden and toxin levels. RNA-seq data indicated that these drugs can promote disease alleviation through increased expression of several innate immune response-related genes previously demonstrated to impact CDI, including those involved in the recruitment of neutrophils, the production of interleukin 33 (IL-33), and the IL-22 signaling pathway [124]. While the specific mechanism of action is unknown, experimental data suggest that the use of innate immunity to combat *C. difficile* occurs indirectly via the gut microbiota, and IL-33-mediated disease alleviation was dependent on the presence of the microbiota [124].

4. Drug re-purposing strategies

4.1. Auranofin

Due to the critical and unmet need for developing new anti-CDI therapeutics, researchers have turned their attention to re-purposing drugs with well-studied safety and pharmacokinetic profiles. Auranofin (6; Figure 2) is a gold-containing anti-inflammatory FDA-approved anti-rheumatoid arthritis drug which possesses strong antibacterial and antifungal activities [125]. Similar to the anticytostidal antibiotic fidaxomicin, auranofin was observed to inhibit *C. difficile* growth, toxin production, and spore formation. Auranofin also produced a direct protective effect against *C. difficile* toxin-mediated inflammation in an *in vitro* assay, which was not observed with fidaxomicin [125,126]. Upon testing in a mouse model of CDI, auranofin significantly protected mice against CDI at low clinically achievable doses (0.125 mg/kg and 0.25 mg/kg) with 100% and 80% survival, respectively. Auranofin is a promising candidate, with an unknown mechanism of action, which warrants further investigation as a novel treatment option for CDI.

4.2. Diiodohydroxyquinoline

Anti-parasitic drugs have also been investigated as anti-clostridial drugs. Diiodohydroxyquinoline (D HQ, 7; Figure 2) is an FDA-approved oral anti-amoebic drug which has demonstrated potent activity against 39 *C. difficile* isolates, displaying superior efficacy to vancomycin and metronidazole in inhibiting toxin production and spore formation, whilst preserving the growth of key species within the intestinal microbiota, such as *Bacteroides, Bifidobacterium,* and *Lactobacillus* spp [127]. The mechanism of action is currently unknown.

4.3. Ronidazole

Ronidazole (8; Figure 2) is a veterinary antiprotozoal drug which like D HQ can inhibit the growth of clinical *C. difficile* isolates, whilst preserving the growth of several commensal organisms in the human intestine. Ronidazole was superior to metronidazole when both were tested at a dose of 1 mg/kg daily in a mouse model of CDI [128]. Like metronidazole, ronidazole is a member of the antibiotic class of nitroimidazoles [128]. Hence, it is anticipated that the nitro group is reduced by the clostridial pyruvate:ferredoxin oxidoreductase to produce imidazole radical and nitrite, both of which are capable of causing damage to the bacterial DNA leading to cell death.

Several other potent anti-clostridial hits, clustered within four chemical groups ([nitroimidazoles *MIC* 50 = 0.06–2.7 μM], salicylanilides *MIC* 50 = 0.2–0.6 μM), imidazole antifungals (*MIC* 50 = 4.8–11.6 μM), and miscellaneous group (*MIC* 50 = 0.4–22.2 μM) have been identified among FDA-approved drugs and are summarized elsewhere [128].
5. Natural products

Several food-grade and plant-derived natural products show demonstrable antimicrobial activity against *C. difficile* in vitro. These have been summarized by Roshan et al. [129,130]. The most active pure compounds against *C. difficile* toxins included zingerone (0.3 mg/mL), and trans-cinnamaldehyde (0.005% v/v). Three *Leptospernum* honeys (4% w/v), and fresh onion bulb extract (12.5% v/v) also significantly reduced toxin production and activity in vitro [129].

Berberine (9; Figure 2) is a poorly absorbed isquinoline alkaloid present in numerous plants of the genera *Berberis* and *Coptis*. In China, berberine has been used as a herbal medicine to treat gastrointestinal disorders for millennia [131]. It possesses a range of pharmacological and biological activities, including anti-inflammatory and antimicrobial properties against bacteria, fungi, parasites, worms, and viruses. The significant antimicrobial function of berberine is mediated through its ability to inhibit the assembly of FtsZ (filamenting temperature-sensitive mutant Z) and halt bacterial cell division [132]. Mice gavaged with berberine (100 mg/kg/day) for 5 days following standard vancomycin treatment were prevented from developing a CDI relapse in a mouse model of CDI [133]. Combined therapy prevented weight loss, improved the disease activity and histopathology scores, and effectively decreased mortality. Berberine also restored vancomycin-induced dysbiosis by inhibiting the expansion of members of the family *Enterobacteriaceae* [133].

High-throughput techniques have also been recently employed to identify new lead molecules with potent anti-clodstridial activity from the AnalytiCon NATx library (consisting of 5000 natural product-inspired or natural product-derived synthetic compounds [134]. Among the panel of hits which underwent validation to confirm anti-clodstridial activity, 10 compounds were found to be capable of inhibiting the pathogen. Out of these, three compounds (NAT13-338,148, NAT18-355,531, and NAT18-3,557,680) showed potent activity against *C. difficile* (MIC = 0.5–2 µg/mL), and interestingly, these compounds had minimal to no effect on the indigenous intestinal microbiota species tested and were nontoxic to a human colorectal adenocarcinoma (Caco-2) cell line [134]. Their mechanisms of action are currently unknown.

6. Trifluoromethylthio-containing compounds

Researchers from Purdue University, US, have recently shown how trifluoromethylthio-containing *N*(1,3,4-oxadiazol-2-yl)benzamides altered with halogen substitutions can protect mice from CDI recurrence more effectively than vancomycin [135]. The most promising of these compounds HSGN-218 (10; Figure 2) demonstrated ultrapotent activities against various *C. difficile* isolates. HSGN-218 is up to 100 times more active [MICs ranging from 0 to 0.003 µg/mL (0.007 µM)] against *C. difficile* clinical isolates than vancomycin, appears to be nontoxic to mammalian colon cells, and is gut-restrictive as demonstrated by its limited ability to permeate across Caco-2 bilayers [135]. Although the precise mechanism of action of HSGN-218 is unknown, the compound belongs to the class of *N*-(1,3,4-oxadiazol-2-yl)benzamide which is known to inhibit the biosynthesis of bacterial lipoteichoic acid [136].

Further details regarding inhibitory activity for a selection of the aforementioned compounds can be found in Table 1.

7. Conclusions

Combating *C. difficile* continues to be a priority. Advances in molecular biology, biochemistry, and immune phenotyping, as well as high-throughput omics-based platforms have opened up a new treasure trove of therapeutic targets (Figure 2). Choosing amongst these and fine-tuning them based on a knowledge of mechanism of action and host genotypes may result in important new adjunctive therapies that are highly targeted and effective, and crucially may be indispensable in overcoming antimicrobial resistance.

8. Expert opinion

Despite significant efforts in recent years to improve the therapeutic armamentarium against *C. difficile*, there remains a major lack of translational bench to bedside success stories. A major barrier is our incomplete understanding of *C. difficile* pathogenesis. Beyond patient characteristics and *C. difficile* ribotype or toxin production, there has been increasing recognition of the nuanced host–pathogen interaction leading to colonization and infection as well as determining disease severity and outcome. An understanding of these intricate interactions can be further accelerated through a systems biology approach to the study of CDI, including the use of high throughput ‘omic’ techniques such as next generation microbial sequencing and immunometabolic assays. How to best analyze and integrate such complex datasets arising from these techniques will require new machine-learning approaches, the development and implementation of which, will continue to challenge the research community. Recognizing the importance of host–microbiome interactions in CDI has also resulted in a shift in treatment strategy. While prevention of growth or killing of vegetative *C. difficile* cells remains important, restoring a disrupted gut microbiome may be even more critical to treatment success. Such insights into the contribution of the gut microbiome and our ability to manipulate the gut microbiome will drive further research in the next 5–10 years.

From a pharmacy and antimicrobial stewardship perspective, *C. difficile* is concerning because treatment options are limited to three antibiotics and there is also the high risk of recurrence. Academic research will continue to play a key role in identifying new drug targets, including understanding target biology but considerable hurdles remain, such as target-safety issues, druggability and assayability, as well as legal, intellectual property, and regulatory issues, all of which are important considerations for academia-industry collaborations. Future intensive efforts must focus on elucidating molecular and pathophysiological mechanisms that underpin susceptibility to primary and recurrent infection and the most severe manifestations of *C. difficile*-associated disease. To address this need, more time and effort should be invested in prioritizing the development of gut infection model systems...
Table 1. Emerging anti-C. difficile therapeutics: inhibitory activity, dose, usage and benefits.

| Drug/treatment | Inhibitory activity | Dose | Usage | Benefits |
|----------------|---------------------|------|-------|----------|
| Repurposed drugs | Amoxapine | MIC > 100 µg/ml – no bactericidal activity | 3 mg/kg, i.p. daily for 3 days | Repurposed - an antidepressant – non-antibiotic FDA-approved drug [124] | Drug-mediated protection was not due to bacterial killing or modulation of toxin production in vivo and has limited impact on the microbiome |
| | Doxapram | MIC > 100 µg/ml – no bactericidal activity | 20 mg/kg, i.p. daily for 3 days | Repurposed – a breathing stimulant – non-antibiotic FDA-approved drug [124] |
| | Trifluoperazine | MIC > 100 µg/ml – no bactericidal activity | 1.5 mg/kg, i.p. (single dose) | Repurposed – an antipsychotic – non-antibiotic FDA-approved drug [124] |
| | Auranofin | MIC90 = 0.5 µg/ml | 0.125 mg/kg and 0.25 mg/kg (mice) | Repurposed – FDA-approved anti-rheumatoid arthritis drug which possesses strong antibacterial and antifungal activities [125]. |
| | Diiodohydroxyquinoline | MIC90 = 0.5 µg/ml | 650 mg/kg – TID 20 days (for amoebiasis) | Repurposed – FDA-approved oral anti-amoebic drug which has potent activity against C. difficile [127] |
| | Ronidazole | MIC = 0.0625 µM | 1 mg/kg daily | Repurposed – Veterinary antiprotozoal drug which like DIHQ can inhibit the growth of clinical C. difficile isolates [112] |
| | Nitroimidazoles | MIC50 = 0.06–2.7 µM | n/a | Repurposed – potent anti-clostridial hits [128] |
| | Salicylanilides | MIC90 = 0.2–0.6 µM | n/a | Not yet tested in animals |
| | Imidazole antifungals | MIC50 = 4.8–11.6 µM | n/a | Not yet tested in animals |
| | Halcin | MIC = 0.5 µg/ml | 200 mg/kg i.p. in mice single daily dose (3 days) | Greater clearance of C. difficile in mice than metronidazole |
| Miscellaneous group | Berberine | MIC vary from 1.024–256 µg/ml | 100 mg/kg/day for 5 days Post Vancomycin | Prevented relapse post vancomycin in a mouse model of CDI [133], isoquinoline alkaloid present in numerous plants, but its not effective against all isolates |
| | NAT13:338,148, NAT18:355,531, and NAT18:3,557,680 | MIC = 0.5–2 µg/ml | n/a | AnalytiCon NATx library – natural product library [134] |
| | Trifluoromethylthio-containing compounds | Trifluoromethylthio-containing N-(1,3,4-oxadiazol-2-yl) benzamidines (HSGN-218) | MIC > 0.007 µM | Ultrapotent small molecule inhibitor of various isolates and protects mice from rCDI [135] |
| FabK targets | Verapamil | MIC50 = 8 µM | n/a | Targets bacterial fatty acid synthesis pathway [70] |
| | Verapamil + efflux inhibitors | MIC50 = 2 µM | n/a | More potent with the addition of efflux inhibitors |

QID = four times daily; TID = three times daily; DIHQ = Diiodohydroxyquinoline; MIC = Minimum inhibitory concentration; i.p. = intraperitoneal
with greater relevance to human disease, such as patient-derived primary cells or induced pluripotent stem cells. These approaches can complement animal and three-tier chemostat models of CDI. Greater emphasis on supporting the immune system to neutralize C. difficile by disarming the synthesis of virulence or pathogenesis factors, and thereby reducing evolutionary pressure for the emergence of resistance, may offer the best approach. Accordingly, drugs targeting certain virulence factors, such as adhesins or toxins, as well as biofilm or spore formation, represent ideal candidates for further intensive exploration. Moreover, host directed therapies are likely to gain traction as prospective adjunctive therapies, which modulate the inflammatory response and restrict immunopathology. However, concerns remain regarding delivery systems and off-target effects. Whilst C. difficile biofilm communities are likely critical in rCDI, several questions remain unanswered regarding the relevance of such biofilm communities in bacterial persistence and the bacterial and host factors regulating their formation in vivo. In terms of toxin inhibitors, it should be borne in mind that the PaLoc Island comprising the main toxins, TcdA and TcdB, are very variable in their composition resulting in multiple toxinotypes. Moreover, the high plasticity of the C. difficile genome is another important challenge for the rationale design of future therapies. Thus, implementing whole-genome sequencing combined with metabolomics approaches, and emerging high-plex digital spatial and molecular profiling technologies will facilitate an unprecedented level of subcellular resolution. These advanced ‘omics’ tools, coupled with machine learning and artificial intelligence methods, will provide better ‘deep’ phenotyping of clinical trial patients, and will help elucidate targets and pathways critical to those processes amenable to pharmacologic modulation. Artificial intelligence can also be used to identify at-risk patients sooner and afford clinicians the opportunity to address modifiable risk factors, thereby proactively preventing CDI using known, evidence-based prevention strategies.

As the cost of developing a new drug remains prohibitively expensive, repurposing of existing approved and investigational drugs such as auranofin, diidohydroxyquinoline and ronidazole may quickly open orthogonal approaches, particularly given known safety profiles and reduction in the cost barrier.

Overall, the implementation of a multidisciplinary team science and an inter-organizational collaborative model will be required to foster innovation and facilitate efficient drug discovery programs. Although target identification is critical to developing new effective compounds for the treatment and prevention of CDI, it is likely that no magic bullet model for CDI is attainable and that only a combination of targets will mediate a full phenotypic effect.

Acknowledgments

We would like to extend our apologies to all our colleagues who were not cited despite our strongest efforts to give credit to the excellent work that has been carried out in the field of C. difficile research.

Funding

BH Mullish is the recipient of an NIHR Academic Clinical Lectureship (CL-2019-21-002). The Division of Digestive Diseases at Imperial College London receives financial and infrastructure support from the NIHR Imperial Biomedical Research Centre (BRC) based at Imperial College Healthcare NHS Trust and Imperial College London. WC Chan, TM Monaghan and L Dawson are supported by a grant from the Medical Research Council Uk, Developmental Pathway Funding Scheme (MR/S019103/1).

Declaration of Interests

TM Monaghan has received consultancy fees from Takeda. BH Mullish has received consultancy fees from Finch Therapeutics Group, MA, USA. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.

ORCID

Tanya M Monaghan https://orcid.org/0000-0001-7622-3997
Benjamin H Mullish https://orcid.org/0000-0001-6300-3100
Lisa F. Dawson https://orcid.org/0000-0003-4644-2368
Dina Kao https://orcid.org/0000-0002-6096-0586

References

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

1. Crobach MJT, Vernon JJ, Loo VG, et al. Understanding Clostridium difficile Colonization. Clin Microbiol Rev. 2018;31(2):e00021–17.
2. Martin JS, Monaghan TM, Wilcox MH. Clostridium difficile infection: epidemiology, diagnosis and understanding transmission. Nat Rev Gastroenterol Hepatol. 2016;13(4):206–216.
3. Fu Y, Luo Y, Grinspan AM. Epidemiology of community-acquired and recurrent Clostridioides difficile infection. Therap Adv Gastroenterol. 2021;14:17562848211016248.
4. Abad CLR, Safdar N. A review of clostridioides difficile infection and antibiotic-associated diarrhea. Gastroenterol Clin North Am. 2021;50(2):323–340.
5. Juneau C, Mendias EN, Wagal N, et al. Community-acquired clostridium difficile infection: awareness and clinical implications. J Nurse Pract. 2013;9(1):1–6.
6. Jaber MR, Olafsson S, Fung WL, et al. Clinical review of the management of fulminant clostridium difficile infection. Am J Gastroenterol. 2008;103(12):3195–3203. quiz 204.
7. Zhang L, Dong D, Jiang C, et al. Insight into alteration of gut microbiota in Clostridium difficile infection and asymptomatic C. difficile colonization. Anaerobe. 2015;34:1–7.
8. Chandrasekar R, Lacy DB. The role of toxins in Clostridium difficile infection. FEMS Microbiol Rev. 2017;41(6):723–750.
9. Awad MM, Johansen PA, Carter GP, et al. Clostridium difficile virulence factors: insights into an anaerobic spore-forming pathogen. Gut Microbes. 2014;5(5):579–593.
10. Tijerina-Rodriguez L, Villareal-Trevino L, Morfin-Otero R, et al. Factors of Clostridiodes (Clostridium) difficile linked to recurrent infections. Can J Infect Dis Med Microbiol. 2019;2019:7127850.
11. Loo VG, Poirier L, Miller MA, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea.

http://orcid.org/0000-0002-6096-0586

http://orcid.org/0000-0001-7622-3997
with high morbidity and mortality. N Engl J Med. 2005;353(23):2442–2449.

12. Wamy M, Pepin J, Fang A, et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet. 2005;366(9491):1079–1084.

13. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis. 2008;47(9):1162–1170.

14. Gupta SB, Mehta V, Dubberke ER, et al. Antibodies to Toxin B are protective against clostridium difficile infection recurrence. Clin Infect Dis. 2016;63(6):730–734.

15. Kyne L, Wamy M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet. 2001;357(9251):189–193.

16. Wilcox MH, Gerdng DN, Poxtor IR, et al. Bezolotoxumab for prevention of recurrent clostridium difficile infection. N Engl J Med. 2017;376(4):305.

**First clinical trial to show anti-toxin B monoclonal antibody (Bezolotoxumab), but not anti-toxin A (Actoxumab) used as an adjunct to anti-cDi antibody was effective at preventing CDi recurrence.**

17. Johnson S, Lavergne V, Skinner AM, et al. Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of clostridioiides difficile infection in adults. Clin Infect Dis. 2021;73(5):e1029–e1044.

18. Kelly CR, Fischer M, Allegretti JR, et al. ACG clinical guidelines: prevention, diagnosis, and treatment of clostridioides difficile infections. Am J Gastroenterol. 2021;116(6):1124–1147.

19. Song JH, Kim YS. Recurrent clostridium difficile infection: risk factors, treatment, and prevention. Gut Liver. 2019;13(1):16–24.

20. van Nood E, Vrieze A, Nieuwpoort M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 365(8):407–415. 2011.

21. First randomised trial demonstrating superior clinical efficacy of fecal microbiota transplantation in treating recurrent CDI patients compared with vancomycin.

22. Administration UFaD. Information pertaining to additional safety protections regarding use of fecal microbiota for transplantation-screening and testing of stool donors for multi-drug resistant organisms https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/information-pertaining-additional-safety-protections-regarding-use-fecal-microbiota-transplantation?utm_campaign=What%27sNew2019-06-18&utm_medium=email&utm_source=Eloqua US Food and Drug Administration; 2019 [FDA Alert].

23. Administration UFaD. Important safety alert regarding use of fecal microbiota for transplantation and risk of serious adverse reactions due to transmission of multi-drug resistant organisms. US Food and Drug Administration. 2020 [https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/important-safety-alert-regarding-use-fecal-microbiota-transplantation-risk-serious-adverse].

24. Kao D, Wong K, Franz R, et al., The effect of a microbial ecosystem therapeutic (MET-2) on recurrent Clostrididioiides difficile infection: a phase 1, open-label, single-group trial. Lancet Gastroenterol Hepatol. 6(4): 282–291. 2021.

25. This pilot open-label study was the first using a defined microbial consortium MET-2, consisting of 40 commensal microorganisms, to successfully treat CDI patients.

26. Khoruts A, Staley C, Sadowsky MJ. Fecal microbiota transplantation for Clostrididioiides difficile: mechanisms and pharmacology. Nat Rev Gastroenterol Hepatol. 2021;18(1):67–80.

27. Segal JP, Mullish BH, Quraishi MN, et al. Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. Therap Adv Gastroenterol. 2020;13:175628420969004.

28. Hong HA, Ferreira WT, Hosseini S, et al. The Spore Coat Protein CoE Facilitates Host Colonization by Clostridium difficile. J Infect Dis. 2017;216(1):1452–1459.

29. Phetcharburan J, Hong HA, Colenutt C, et al. The spore-associated protein BcIa1 affects the susceptibility of animals to colonization and infection by Clostrididioiides difficile. Mol Microbiol. 2014;92(5):1025–1038.

30. Castro-Cordova P, Mora-Uribe P, Reyes-Ramirez R, et al. Entry of spores into intestinal epithelial cells contributes to recurrence of Clostrididioiides difficile infection. Nat Commun. 2021;12(1):1140.

31. Maia AR, Reyes-Ramirez R, Pizarro-Guajardo M, et al. Nasal Immunization with the C-Terminal Domain of BcIa3 induced specific IgG production and attenuated disease symptoms in mice infected with Clostrididioiides difficile spores. Int J Mol Sci. 2020;21(18):6966.

32. Fagan RP, Fairweather NF. Biogenesis and functions of bacterial S-layers. Nat Rev Microbiol. 2014;12(3):211–222.

33. Merrigan MM, Venugopal A, Roxas JL, et al. Surface-layer protein A (SlpA) is a major contributor to host-cell adherence of Clostrididioiides difficile. PLoS One. 2013;8(11):e78404.

34. Bruxelle JF, Mizrahi A, Hous S, et al. Immunogenic properties of the surface layer precursor of Clostrididioiides difficile and vaccination assays in animal models. Anaerobe. 2016;37:78–84.

35. Vedantam G, Kochanowsky J, Lindsey J, et al. An engineered synthetic biologic protects against Clostridium difficile infection. Front Microbiol. 2018;9:2080.

36. Tasteyre A, Barc MC, Collignon A, et al. Role of FltC and FltD flagellar proteins of Clostridium difficile in adherence and gut colonization. Infect Immun. 2001;69(12):7937–7940.

37. Bruxelle JF, Tsapis N, Hous S, et al. Protection against Clostridium difficile infection in a hamster model by oral vaccination using flagellin FltC-loaded pectin beads. Vaccine. 2018;36(40):6017–6021.

38. Anjuwon-Foster BR, Tamayo R. A genetic switch controls the production of flagella and toxins in Clostridium difficile. PLoS Genet. 2017;13(3):e1006701.

39. Anjuwon-Foster BR, Maldonado-Vazquez N, Tamayo R. Characterization of flagellum and toxin phase variation in Clostridium difficile ribotype 012 isolates. J Bacteriol. 2018;200(14):e00056–18.

40. Semenyuk EG, Poroyko VA, Johnston PF, et al. Analysis of bacterial communities during Clostridium difficile infection in the mouse. Infect Immun. 2015;83(11):4383–4391.

41. Buckley AM, Spencer J, Candelis D, et al. Infection of hamsters with the UK Clostridium difficile ribotype 027 outbreak strain RO2091. J Med Microbiol. 2011;60(8):1174–1180.

42. Normanlig M, Moura IB, Bryant JA, et al. Biofilms harbour Clostrididioiides difficile, serving as a reservoir for recurrent infection. NPJ Biofilms Microbiomes. 2021;7(1):16.

43. Ethapa T, Leuzzi R, Ng YK, et al. Multiple factors modulate biofilm formation by the anaerobic pathogen Clostridium difficile. J Bacteriol. 2013;195(2):545–555.

44. Dawson LF, Peltier J, Hall CL, et al. Extracellular DNA, cell surface proteins and c-di-GMP promote biofilm formation in Clostrididioiides difficile. Sci Rep. 2021;11(1):3244.

45. Lee AS, Song KP. LuxS/autotinducer-2 quorum sensing molecule regulates transcriptional virulence gene expression in Clostridium difficile. Biochem Biophys Res Commun. 2005;335(3):659–666.

46. Slater RT, Frost LR, Jossi SE, et al. Clostrididioiides difficile LuxS mediates inter-bacterial interactions within biofilms. Sci Rep. 2019;9(1):9903.

47. Martinez-Melendez A, Morfin-Otero R, Villarrel-Trevino L, et al. Analysis of biofilm production and expression of adhesion structures of circulating Clostrididioiides difficile strains from Mexico. Enferm Infeccc Microbiol Clin (Engl Ed). 2021;52(3):00042. 10.1016/j.eijmic.2021.01.017.

48. Dawson LF, Valiente E, Faulds-Pain A, et al. Characterisation of Clostridium difficile biofilm formation, a role for Sp0A. PLoS One. 2012;7(12):e50527.

49. Engevik MA, Danhof HA, Aucltung J, et al. Fusobacterium nucleatum adheres to Clostridium difficile via the RadD adhesin to enhance biofilm formation in intestinal mucus. Gastroenterology. 2021;160(4):1301–14 e8.
48. Selmer T, Andrei PI. p-Hydroxyphenylacetate decarboxylase from Clostridium difficile. A novel glycol radical enzyme catalysing the formation of p-cresol. Eur J Biochem. 2001;268(3):1363–1372.

49. Harrison MA, Faulds-Pain A, Kaur H, et al., Clostridioides difficile para-cresol production is induced by the precursor para-hydroxyphenylacetate. J Bacteriol. 2021;18(2):e00282–20. 2020.

- **First study to show disassembly and inhibition of biofilm formation with DNase in *C. difficile** enhanced the efficacy of vancomycin.

50. Dawson LF, Donauhe EH, Cartman ST, et al. The analysis of para-cresol production and tolerance in Clostridium difficile 027 and 012 strains. BMC Microbiol. 2011;11(1):86.

51. Passmore UJ, Letetrre MPM, Preston MD, et al., Para-cresol production by Clostridium difficile affects microbial diversity and membrane integrity of Gram-negative bacteria. PLoS Pathog. 14(9): e1007191. 2018.

- **First study to show para-cresol production by *C. difficile* promotes intestinal dysbiosis by targeting the membrane-integ of Gram-negative bacteria, which provides *C. difficile* with a competitive growth advantage.

52. Saito Y, Sato T, Nomoto K, et al., Identification of phenol- and p-cresol-producing intestinal bacteria by using media supplemented with tyrosine and its metabolites. FEMS Microbiol Ecol. 2018;94(9): fyj125.

53. Dawson LF, Valiente E, Donauhe EH, et al., Hypervirulent Clostridium difficile PCR-ribotypes exhibit resistance to widely used disinfectants. PLoS One. 2011;6(10):e25754.

54. Staples E, The zNose, a new electronic nose using acoustic tech jology. J Acoust Soc Am. 2000;108(5):2495.

55. Abedon ST, Kuhl SJ, Blasdel BG, et al., Phage treatment of human infections. Bacteriophage. 2011;1(2):66–85.

56. Schmelcher M, Donovan DM, Loesner MJ. Bacteriophage endolysins as novel antimicrobials. Future Microbiol. 2012;7(10):1147–1171.

57. Mondal S, Akter A, Draper LA, et al., Characterization of an endolysin targeting clostridioides difficile that affects spore outgrowth. Int J Mol Sci. 2021;22(11):5690.

58. Mayer MJ, Garefakli V, Spoerl R, et al., Structure-based modification of a Clostridium difficile-targeting endolysin affects activity and host range. J Bacteriol. 2011;193(19):5477–5486.

59. Mehta KK, Paskaleva EE, Wu X, et al., Newly identified bacteriolytic enzymes that target a wide range of clinical isolates of Clostridium difficile. Biotechnol Bioeng. 2016;113(12):2568–2576.

60. Heuler J, Fortier LC, Sun X. Clostridioides difficile phage biology and application. FEMS Microbiol Rev. 2021;45(5):fuaa012.

61. de Mendoza DSG. Lipid Biosynthesis. In: Encyclopedia of microbiology. 4th ed. 2014. p. 780–790.

62. Parsons JB, Rock CO. Bacterial lipids: metabolism and membrane homeostasis. Prog Lipid Res. 2013;52(3):249–276.

63. Lu H, Tonge PJ. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway. Acc Chem Res. 2008;41(1):11–20.

64. Heath RJ, Rock CO. A triclosan-resistant bacterial enzyme. Nature. 2000;406(6792):145–146.

65. Zhu L, Lin J, Ma J, et al., Triclosan resistance of Pseudomonas aeruginosa PA01 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase. Antimicrob Agents Chemother. 2010;54(2):689–698.

66. Marrakchi H, Dewolf WE Jr., Quinn C, et al., Characterization of Streptococcus pneumoniae enolyl-(acyl-carrier protein) reductase (FabK). Biochem J. 2003;370(3):1035–1062.

67. Zheng CJ, Sohn MJ, Kim WG. Atromentin and leukemolone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae. J Antibiot (Tokyo). 2006;59(12):808–812.

68. Kitagawa H, Ozawa T, Takahata S, et al., Phenylimidaole derivatives as new inhibitors of bacterial enoyl-ACP reductase FabK. Bioorg Med Chem Lett. 2007;17(17):4982.

69. Marreddy RKR, Wu X, Sapkota M, et al., The fatty acid synthesis protein Enoyl-ACP reductase II (FabK) is a target for narrow-spectrum antibacterials for Clostridium difficile infection. ACS Infect Dis. 5(2): 689–698. 2019.

- **First study to show that FabK is the sole enoyl-ACP isomerase in *C. difficile*.

70. Jones JA, Prior AM, Marreedy RKR, et al., Small-Molecule Inhibition of the *C. difficile* FAS-II enzyme, fabk, results in selective activity. ACS Chem Biol. 2019;14(7):808–812.

71. Tam J, Beilhartz GL, Auger A, et al., Small molecule inhibitors of Clostridium difficile toxin B-induced cellular damage. Chem Biol. 2015;22(2):175–185.

- This study indicates the potential of high-throughput screens in the generation of anti-toxin drugs by identification of an array of diverse structures with variable modes of action.

72. Tam J, Icho S, Utama E, et al., Intestinal bile acids directly modulate the structure and function of *C. difficile* TcdB toxin. Proc Natl Acad Sci U S A. 117(12): 6792–6800. 2020.

- **First study to describe the ability of bile acids to modulate structure and function of *C. difficile* TcdB toxin.

73. Howerton A, Seymour CO, Murugapiran SK, et al. Effect of the synthetic bile salt analog CamiSA on the hamster model of *Clostridium difficile* infection. Antimicrob Agents Chemother. 2018;62(10):e02251–17.

74. Bender KO, Garland M, Ferreyra JA, et al., A small-molecule anti-virulence agent for treating *Clostridium difficile* infection. Sci Transl Med. 2015;7(306):306ra148.

75. Beilhartz GL, Tam J, Zhang Z, et al. Comment on "A small-molecule anti-virulence agent for treating *Clostridium difficile* infection." Sci Transl Med. 2016;8(370):370ct2.

76. Simeon R, Jiang M, Chamoun-Emanueli AM, et al., Selection and characterization of ultrahigh potency designed ankyrin repeat protein inhibitors of *C. difficile* toxin B. PLoS Biol. 2019;17(6):e3000311.

77. Xu X, Godoy-Ruiz R, Adipietro KA, et al., Structure of the cell-binding component of the *Clostridium difficile* binary toxin reveals a di-heptameric macromolecular assembly. Proc Natl Acad Sci U S A. 117(2): 1049–1058. 2020.

- **First description of structure of cell-binding component of *Clostridium difficile* binary toxin.

78. Kudryashova E, Sveevo SM, Kudryashov DS. Targeting and inactiva of bacterial toxins by human defensins. Biol Chem. 2017;398 (10):1069–1085.

79. Giesemann T, Guttenberg G, Aktories K. Human alpha-defensins inhibit *Clostridium difficile* toxin B. Gastroenterology. 2008;134 (7):2049–2058.

- **First experimental proof that human alpha-defensins can inhi t TcdB-induced cytotoxicity in human cells.

80. Korbmacher M, Fischer S, Landenberger M, et al., Human alpha-defensin-5 efficiently neutralizes Clostridioides difficile Toxins TcdA, TcdB, and CDT. Front Pharmacol. 2020;11:1204.

81. Fischer S, Uckert AK, Landenberger M, et al., Human peptide alpha-defensin-1 interferes with Clostridioides difficile toxins TcdA, TcdB, and CDT. FASEB J. 2020;34(5):6244–6261.

82. Krautkramer KA, Fan J, Backhed F. Gut microbial metabolites as multi-kingdom intermediates. Nat Rev Microbiol. 2021;19(2):77–94.

83. Martinez-Gili L, McDonald JAK, Liu Z, et al., Understanding the mechanisms of efficacy of fecal microbiota transplant in treating recurrent Clostridiodes difficile infection and beyond: the contribu of gut microbial-derived metabolites. Gut Microbes. 2020;12 (1):1810531.

84. Sorg JA, Sonenshein AL. Bile salts and glycin e as cogemnants *for* Clostridium difficile spores. J Bacteriol. 2008;190(7):2505–2512.

- **First experimental evidence that bile salts were key to germination of *C. difficile* spores.

85. Thanissery R, Winston JA, Theriot CM. Inhibition of spore germination, growth, and toxin activity of clinically relevant *C. difficile* strains by gut microbiota derived secondary bile acids. Anaerobe. 2017;45:86–100.

86. Ridlon JM, Kang DJ, Hylemon PB. Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2006;47(2):241–259.

87. Weingarden AR, Chen C, Bobr A, et al., Microbiota transplantation restores normal fecal bile acid composition in recurrent *Clostridium difficile* infection. Am J Physiol Gastrointest Liver Physiol. 306(4): G310–9. 2014.
**First key evidence linking perturbed stool bile acid profiles in rCDI with their restoration post fecal microbiota transplant.**

88. Allegretti JR, Kearney S, Li N, et al. Recurrent Clostridium difficile infection associates with distinct bile acid and microbiome profiles. Aliment Pharmacol Ther. 2016;43(11):1142–1153.

89. Brown JR, Flemen B, Joyce SA, et al. Changes in microbiota composition, bile and fatty acid metabolism, in successful faecal microbiota transplantation for Clostridiodessi difficile infection. BMC Gastroenterol. 2018;18(1):131.

90. Mullish BH, McDonald JAK, Pechlanivis A, et al. Microbial bile salt hydrolases mediate the efficacy of faecal microbiota transplant in the treatment of recurrent Clostridiodessi difficile infection. Gut. 2019;68(10):1791–1800.

91. Seekatz AM, Theriot CM, Rao K, et al. Restoration of short chain fatty acids and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostrididium difficile infection. Anaerobe. 2018;53:64–73.

92. Buffie CG, Bucci V, Stein RR, et al., Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature. 517(7533):205–208. 2015.

**First in vivo model to identify the role of bile acid production by C. scindens in inhibition of C. difficile growth.**

93. Studer N, Desharnais L, Beutler M, et al. Functional intestinal bile acid 7alpha-Dehydroxylation by Clostridium scindens associated with protection from Clostrididium difficile infection in a gnotobiotic mouse model. Front Cell Infect Microbiol. 2016;6:191.

94. Thomas LA, King A, French GL, et al. Cholylglycine hydrolase and 7alpha-dehydrolase optimum assay conditions in vitro and caecal enzyme activities ex vivo. Clin Chim Acta. 1997;268(1–2):61–72.

95. Ocvirk S, O’Keefe SJ. Influence of bile acids on colorectal cancer risk: potential mechanisms mediated by diet-gut microbiota interactions. Curr Nutr Rep. 2017;6(4):315–322.

96. Stoltz KL, Erickson R, Staley C, et al. Synthesis and biological evaluation of bile acid analogues inhibitory to Clostridium difficile spore germination. J Med Chem. 2017;60(8):3451–3471.

97. Sharma SK, Yip C, Esposito EX, et al. The Design, Synthesis, and Characterizations of Spore Germination Inhibitors Effective against an Epidemic Strain of Clostridiodessi difficile. J Med Chem. 2018;61 (15):6759–6778.

98. Monaghan T, Mullish BH, Patterson J, et al., Effective fecal microbiota transplantation for recurrent Clostridiodessi difficile infection in humans is associated with increased signalling in the bile acid farnesoid X receptor-fibroblast growth factor pathway. Gut Microbes. 10(2):142–148. 2019.

**Evidence from human, in vitro and mouse experiments identifying restoration of short chain fatty acids (in particular, valerate) by fecal microbiota transplant as a mechanism of treatment efficacy.**

99. Jose S, Mukherjee A, Horrigan O, et al. Obeticholic acid ameliorates severity of Clostridiodessi difficile infection in high fat diet-induced obese mice. Mucosal Immunol. 2021;14(2):500–510.

100. Winston JA, Rivera AJ, Cai J, et al. Ursodeoxycholic Acid (UDCA) mitigates the host inflammatory response during Clostridiodessi difficile infection by altering gut bile acids. Infect Immun. 2020;88(6):e00045–20.

101. McDonald JAK, Mullish BH, Pechlanivis A, et al. Inhibiting growth of Clostridiodessi difficile by restoring valerate, produced by the intestinal microbiota. Gastroenterology. 2018;155(5):1495–507 e15.

102. McDonald JAPJ, Lopez Perez, J, and Mullish BH, et al. Growth inhibition of Clostridiodessi difficile by short and medium chain fatty acids. Digestive Diseases Week. 2019:S898.

103. Yang HT, Chen JW, Rathod J, et al. Lauric acid is an inhibitor of clostrididium difficile growth in vitro and reduces inflammation in a mouse infection model. Front Microbiol. 2017;8:2635.

104. Scott SA, Fu J, Chang PV. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A. 2020;117(32):19376–19387.

105. Zumla A, Rao M, Wallis RS, et al. Host-directed therapies for infectious diseases: current status, recent progress, and future prospects. Lancet Infect Dis. 2016;16(4):e47–63.

106. Huang J, Kelly CP, Bakirtzi K, et al. Clostridium difficile toxins induce VEGF-A and vascular permeability to promote disease pathogenesis. Nat Microbiol. 2019;4(2):269–279.

107. Das S, Jayaratne R, Barrett KE. The role of ion transporters in the pathophysiology of infectious diarrhea. Cell Mol Gastroenterol Hepatol. 2018;6(1):33–45.

108. Hayashi H, Szaszi K, Coady-Osberg N, et al., Inhibition and redistribution of NHE3, the apical Na+/H+ exchanger, by Clostrididium difficile toxin B. J Gen Physiol. 123(5):491–504. 2004.

**The first study to show that C. difficile toxin B inhibits and redistributes the apical Na+/K+ exchanger NHE3 in intestinal epithelial cell lines.**

109. Engervik MA, Engervik KA, Yachshyn MB, et al., Human Clostridium difficile infection: inhibition of NHE3 and microbiota profile. Am J Physiol Gastrointest Liver Physiol. 308(6):G497–509. 2015.

**First study to demonstrate that colonic biopsy specimens from CDI patients show decreased NHE3 expression.**

110. Yu Q. SIC26a3 (DRA) in the gut: expression, function, regulation, role in infectious diarrhea and inflammatory bowel disease. Inflamm Bowel Dis. 2021;27(4):1495–1507 e15.

111. Coffing H, Priaymavada S, An A, et al., Clostridium difficile toxins A and B decrease intestinal SLC26A3 protein expression. Am J Physiol Gastrointest Liver Physiol. 315(1):G43–G52. 2018.

**This study demonstrates that C. difficile toxins markedly down-regulate intestinal expression of DRA(CI/-/HC03- exchanger) which may contribute to the diarrhoeal phenotype of CDI.**

112. Raheja G, Singh V, Ma K, et al. Lactobacillus acidophilus stimulates the expression of SLC26A3 via a transcriptional mechanism. Am J Physiol Gastrointest Liver Physiol. 2010;298(3):G395–401.

113. Singla A, Kumar A, Priaymavada S, et al. LPA stimulates intestinal DRA gene transcription via LPAR2 receptor, PI3K/AKT, and c-Fos-dependent pathway. Am J Physiol Gastrointest Liver Physiol. 2013;302(6):G618–22.

114. Singla A, Dwivedi A, Saksena S, et al. Mechanisms of lysophosphatic acid (LPA) mediated stimulation of intestinal apical CI-/OH- exchange. Am J Physiol Gastrointest Liver Physiol. 2010;298(2):G182–9.

115. Lin R, Murtazina R, Cha B, et al. D-glucose acid cotransporter 1 to increase NHE3 in mouse jejunal brush border by a Na+/H+ exchange regulatory factor 2-dependent process. Gastroenterology. 2011;140(2):560–571.

116. Lin S, Yerua H, He P, et al. Lysophosphatic acid stimulates the intestinal brush border Na+/H+ (+) exchange 3 and fluid absorption via LPAS(5) and NHERF2. Gastroenterology. 2010;138(2):649–658.

117. Al-Sadi R, Engers J, Abdulqadir R. Talk about micromanaging: Role of microRNAs in intestinal barrier function. Am J Physiol Gastrointest Liver Physiol. 2020;319(2):G170–G4.

118. Monaghan TM, Seekatz AM, Markham NO, et al., Fecal microbiota transplantation for recurrent Clostrididium difficile infection associates with functional alterations in circulating microRNAs. Gastroenterology. 161(1):255–270.e4. 2021.

**First study to show that successful FMT for rCDI associates with upregulation of circulating and colonic mucosal microRNAs which target inflammatory genes and show cytoprotective effects against TcdB.**

119. Jarchum I, Liu M, Shi C, et al. Critical role for MyD88-mediated neutrophil recruitment during Clostridium difficile colitis. Infect Immun. 2012;80(9):2989–2996.

120. Saleh MM, Frisbee AL, Leslie J, et al. Colitis-Induced TH17 cells increase the risk for severe subsequent Clostridium difficile Infection. Cell Host Microbe. 2019;25(5):756–65 e5.

121. Frisbee AL, Saleh MM, Young MK, et al. IL-33 drives group 2 innate lymphoid cell-mediated protection during Clostridium difficile infection. Nat Comm. 2019;10(1):2712.

122. Donlan AN, Simpson ME, Petri WA Jr. Type 2 cytokines IL-4 and IL-5 reduce severe outcomes from Clostrididium difficile infection. Anaerobe. 2020;66:102275.

123. Abhyankar MM, Ma JZ, Scully KW, et al. Immune profiling to predict outcome of Clostridiodessi difficile Infection. mBio. 2020;11(3):3.
124. Andersson JA, Peniche AG, Galindo CL, et al. New host-directed therapeutics for the treatment of Clostridioides difficile infection. mBio. 2020;11(2):e00053–20.

125. AbdelKhalek A, Abutaleb NS, Mohammad H, et al. Antibacterial and antivirulence activities of auranofin against Clostridium difficile. Int J Antimicrob Agents. 2019;53(1):54–62.

126. Abutaleb NS, Seleem MN. Auranofin, at clinically achievable dose, protects mice and prevents recurrence from Clostridioides difficile infection. Sci Rep. 2020;10(1):7701.

127. Abutaleb NS, Seleem MN. Repurposing the antiamoebic drug diiodohydroxyquinoline for treatment of Clostridioides difficile infections. Antimicrob Agents Chemother. 2020;64(6):e02115–19.

128. AbdelKhalek A, Mohammad H, Mayhoub AS, et al. Screening for potent and selective antclostridial leads among FDA-approved drugs. J Antimicrob Chemother (Tokyo). 2020;73(6):392–409.

129. Roshan N, Riley TV, Knight DR, et al. Effect of natural products on the production and activity of Clostridium difficile toxins in vitro. Sci Rep. 2018;8(1):15735.

130. Roshan N, Riley TV, Hammer KA. Antimicrobial activity of natural products against Clostridium difficile in vitro. J Appl Microbiol. 2017;123(1):92–103.

131. Birdsall TC. Berberine: therapeutic potential of an alkaloid found in several medicinal plants. Altern Med Review. 1997;2(2):94–103.

132. Domadia PN, Bhunia A, Sivaraman J, et al. Berberine targets assembly of Escherichia coli cell division protein FtsZ. Biochemistry. 2008;47(10):3225–3234.

133. Lv Z, Peng G, Liu W, et al. Berberine blocks the relapse of Clostridium difficile infection in C57BL/6 mice after standard vancomycin treatment. Antimicrob Agents Chemother. 2015;59(7):92–103.

134. Pal R, Dai M, Seleem MN. High-throughput screening identifies a novel natural product-inspired scaffold capable of inhibiting Clostridioides difficile growth, which suppresses recurrence in vivo. J Med Chem. 2020;63(20):11934–11944.

135. Naclerio GA, Abutaleb NS, Li D, et al. Ultrapotent inhibitor of clostridioides difficile growth, which suppresses recurrence in vivo. J Med Chem. 2019;63(20):11934–11944.

136. Naclerio GA, Karanja CW, Opoku-Temeng C, et al. Antibacterial small molecules that potently inhibit staphylococcus aureus lipo- teichoic acid biosynthesis. ChemMedChem. 2019;14(10):1000–1004.